Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ethismos Research Inc. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution effort is concentrated under 1 distinct examiner and 1 distinct art unit, reflecting a very specific technical focus for the company's current filings. This concentration is common in the biotech sector where a single core technology may be the primary subject of patent activity.
The busiest examiner, MCANANY, JOHN D, is handling the 1 busiest examiner pending action. This consolidation means that the company's immediate patent outcomes are dependent on the examination style and technical interpretations of this single official. For practitioners, this highlights the importance of understanding the specific precedents and scientific viewpoints held by MCANANY, JOHN D. The presence of only 1 pending action suggests a focused and perhaps early-stage prosecution strategy that relies on the success of this individual application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCANANY, JOHN D | 1 | 65.1% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17899107 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | MCANANY, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17899107 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | MCANANY, JOHN D | 1625 | §103 | Non-Final OA | — | Pending | Aug 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEthismos Research Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John D Mcanany has the most, with 1 of Ethismos Research Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
